Introducing the synergistic triplet combination of Menin inhibitors with HMA and venetoclax (HMA / VEN) into the first‐line treatment NPM1‐mutated or KMT2A‐rearranged AML patients unfit for intensive chemotherapy is the most obvious next step in the clinical development of these agents. This evidence concerns the gene MEN1 and acute myeloid leukemia.